Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 2,795 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Combination Group Clear all

Conditions: Thrombocytopenia
Interventions: Not listed
Lead sponsor: Christiana Care Health Services; Other
Eligibility: Up to 12 Months
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 4
States / cities: Newark, Delaware • Wilmington, Delaware • Abington, Pennsylvania + 1 more

Conditions: HIV
Interventions: NIATx + ECHO; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 1,450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Diabetes, Wound Infection, Healthy Volunteers
Interventions: Ceftolozane/tazobactam, Microdialysis Catheter Insertion; Drug · Procedure
Lead sponsor: Hartford Hospital; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Hypertension, Vascular Stiffness, Aging
Interventions: Blood pressure treatment algorithm; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 60 Years and older
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Birmingham, Alabama • Nashville, Tennessee • Madison, Wisconsin

Conditions: Traumatic Brain Injury, TBI, Diffuse Axonal Brain Injury, Brain Injuries, Traumatic
Interventions: Combined (Robotic balance training and high-definition transcranial direct current stimulation), Standard of Care Balance Training; Device · Other
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: panitumumab, everolimus, fluorouracil, leucovorin calcium, oxaliplatin; Biological · Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: COVID-19, Long Haul
Interventions: Ritonavir-Boosted Nirmatrelvir (Paxlovid), Physiological Evaluation, Moderna COVID-19 Vaccine, Biopsychological, Behavioral (e.g., Psychotherapy, Lifestyle Counseling), Genetic (including gene transfer, stem cell and recombinant DNA), Multidisciplinary approach; Drug · Diagnostic Test · Biological + 3 more
Lead sponsor: Well- Konnect Healthcare Services and Research Firm; Network
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Interventions: Fuzuloparib , Abiraterone acetate and Prednisone, Fuzuloparib Placebo， Abiraterone acetate and Prednisone; Drug
Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 17
States / cities: Anchorage, Alaska • Tucson, Arizona • Rancho Mirage, California + 13 more

Conditions: Hypertension
Interventions: amlodipine and olmesartan medoxomil tablets, hydrochlorothiazide tablets; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 999 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 72
States / cities: Birmingham, Alabama • Green Valley, Arizona • Mesa, Arizona + 69 more

Conditions: Lupus Erythematosus, Systemic, Lupus Nephritis
Interventions: CTLA4-IgG4m (RG2077), Cyclophosphamide; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 2
States / cities: San Francisco, California • New York, New York

Conditions: Asthma
Interventions: Flovent Diskus, Home Environmental Intervention, Advair Diskus; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 5 Years to 17 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Adolescent, Depression, Substance Use Disorders
Interventions: Adolescent Coping With Depression/Functional Family Therapy; Behavioral
Lead sponsor: Oregon Research Institute; Other
Eligibility: 13 Years to 17 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Eugene, Oregon

Conditions: Hypertension
Interventions: Intensive control of SBP, Standard control of SBP; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 50 Years and older
Enrollment: 9,361 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2019
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Rotator Cuff Tears, Postoperative Pain
Interventions: Liposomal bupivacaine, Bupivacaine Hcl 0.5% Inj, Dexamethasone; Drug
Lead sponsor: Rothman Institute Orthopaedics; Other
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cardiac Transplant Disorder
Interventions: Stratified Transplant Survival; Other
Lead sponsor: Carnegie Mellon University; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Spastic Hemiparesis
Interventions: Botulinum toxin type A, GSC; Biological · Other
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 6
States / cities: Kansas City, Kansas • Pittsburgh, Pennsylvania • Charleston, South Carolina + 3 more

Conditions: Cigarette Smoking, Overweight, Obesity
Interventions: Weight gain prevention and smoking cessation, Smoking cessation; Behavioral
Lead sponsor: Consumer Wellness Solutions; Industry
Eligibility: 18 Years and older
Enrollment: 2,540 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Pancreatic Cancer, Unresectable Pancreatic Cancer, Metastatic Pancreatic Cancer, KRAS P.G12C
Interventions: Sotorasib, Liposomal Irinotecan (nal-IRI), 5 Fluorouracil (5FU), Leucovorin (LV), Gemcitabine (GEM), Nab paclitaxel; Drug
Lead sponsor: Devalingam Mahalingam; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Budesonide/formoterol pMDI, Budesonide pMDI, Formoterol Turbuhaler; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 143
States / cities: Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 140 more

Conditions: Depression, Mild Cognitive Impairment
Interventions: Donepezil, Placebo, Citalopram, Venlafaxine; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 55 Years to 95 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 2
States / cities: New York, New York • Durham, North Carolina

Conditions: Kidney Transplant, Hepatitis C, HCV
Interventions: Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET]; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Obesity, Multiple Chronic Conditions
Interventions: Prescriptive, Behavioral; Other · Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 65 Years to 85 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Acne Vulgaris
Interventions: adapalene 0.1% and benzoyl peroxide 2.5% topical gel, EPIDUO, Placebo (Vehicle Gel); Drug
Lead sponsor: Actavis Mid-Atlantic LLC; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 885 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 8
States / cities: Fremont, California • Miami, Florida • Miramar, Florida + 5 more

Conditions: Unilateral Spatial Neglect, Stroke
Interventions: Prism adaptation training combined with TENS, PAT only; Device · Other
Lead sponsor: Kettering Health Network; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Centerville, Ohio

Search by objective public record fields.

Transfusing Neonates Based on Platelet Mass

Peru Decentralized HIV Care

Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients With Lower Limb Infections

Arterial Stiffness and Blood Pressure

NEUROBALANCE Training to Improve Postural Control in Individuals With Traumatic Brain Injury

Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Tumors That Did Not Respond to Treatment

Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure

Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)

Environmental Control as Add-on Therapy in Childhood Asthma

Sequenced vs. Integrated Delivery of Treatment for Adolescent Depression and SUD

Systolic Blood Pressure Intervention Trial

Exparel v Dexamethasone in RCR

Don't Throw Your Heart Away: Medical Student Study 2

Study to Evaluate Effects of DYSPORT® Injected in Lower and Upper Limb Combined With Guided Self-Rehabilitation Contract (GSC)

Comparative Effectiveness of Adding Weight Control to Smoking Cessation Quitlines

Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer

A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients

Combination Treatment Study for Memory Impairment and Depression

Utilization of Hepatitis C Positive Kidneys in Negative Recipients

Optimizing Telehealth-delivery of a Weight Loss Intervention in Older Adults

A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) in the Treatment of Mild to Severe Acne Vulgaris

Comparing Prism Adaptation Training With and Without TENS to Minimize Unilateral Spatial Neglect